Adma Biologics (ADMA) FY2019 results: revenue $29 million, up 72.8% on the year
Adma Biologics, Inc. (ADMA) reported revenue of $29 million for fiscal 2019, the year ended 31 December 2019, up 72.8% on the year before. Net income was -$48 million, and diluted earnings per share $-0.89. The figures are the company's own, from the 10-K it filed with the SEC on 13 March 2020.
Revenue
$29 million
+72.8% on the year
FY2012FY2019
Operating margin
-141.1%
-354.9% a year earlier
FY2012FY2019
Net income
-$48 million
FY2012FY2019
Diluted EPS
-$0.89
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
29.3
17.0
22.8
+72.8%
Cost of revenue
39.5
42.2
29.2
-6.4%
Gross profit
-10.2
-25.2
-6.4
Gross margin
-34.6%
-148.4%
-28.1%
Research and development
2.3
3.9
5.6
-40.3%
Operating income
-41.4
-60.3
-39.3
Operating margin
-141.1%
-354.9%
-172.7%
Interest expense
9.0
5.5
3.3
+62.8%
Income tax
0.0
0.0
0.0
Net income
-48.3
-65.7
-43.8
Net margin
-164.5%
-387.1%
-192.3%
Diluted EPS
-$0.89
-$1.45
-$1.91
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
-76.2
-62.7
-37.3
Capital expenditure
3.8
2.1
2.7
+81.9%
Free cash flow
-80.0
-64.8
-39.9
Free cash flow margin
-272.6%
-381.4%
-175.5%
Cash from investing
-3.8
-2.1
15.2
Cash from financing
80.0
42.9
60.8
+86.4%
Depreciation and amortisation
2.4
2.6
1.5
-7.7%
Share-based compensation
2.7
2.2
1.6
+19.2%
Shares outstanding at period end
59m
46m
37m
+28.0%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
26.2
19.8
40.3
+32.5%
Debt
83.2
44.1
43.0
+88.8%
Other liabilities
17.7
25.0
24.7
-29.3%
Total liabilities and equity
127
88.9
108
+43.0%
Fixed assets
31.7
30.1
30.5
+5.4%
Goodwill
3.5
3.5
3.5
0.0%
Intangible assets
3.2
4.0
4.8
-21.1%
Investments
n/a
n/a
0.0
Cash and equivalents
26.8
26.8
43.1
-0.0%
Receivables
3.5
1.4
3.9
+149.2%
Inventory
53.1
18.6
12.6
+185.0%
Other assets
5.4
4.5
9.6
+20.4%
Total assets
127
88.9
108
+43.0%
10-K for the year ended 31 December 2019, filed 13 March 2020: the filing.